Nonsteroidal-anti-inflammatory drugs and serious undesirable gastrointestinal effects;Nesteroidni protuupalni lijekovi i ozbiljne gastrointestinalne nuspojave

Lijecnicki Vjesnik

Volumn 129, Issue 6-7, 2007, Pages 205-213

  Fabijanić, Damir ^a,c   Kardum, Duško ^b   Banič, Marko ^b   Fabijanić, Antonija ^c  

^a Klinika za Unutarnje Bolesti

^b University of Zagreb School of Medicine

^c Pedijatrijska Ordinacija ^*

Author keywords

Adverse effects, pharmacology, therapeutic use; Gastrointestinal diseases; Anti inflammatory agents, non steroidal; Chemically induced, prevention and control; Gastric mucosa; Drug effects, pathology

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; CHEMICALLY INDUCED DISORDER; GASTROINTESTINAL DISEASE; HUMAN;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; GASTROINTESTINAL DISEASES; HUMANS;

EID: 34548591936     PISSN: 00243477     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (77)

1. Brooks P, Emeray P, Evans JF i sur. Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2. Rheumatology (Oxford) 1999; 38:779-88.
2. Hennekens CH, Dyken MC, Fuster V. Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1997; 96:2751-3.
3. Talley NJ, Evans JM, Fleming KC i sur. Nonsteroidal antiinflammatory drugs and dyspepsia in the elderly. Dig Dis Sci 1995; 40:1345-50.
4. Retail & Provider Perspective, National Prescription Audit, 1999-2000. Plymouth: IMS Health; 2000.
5. Singh G, Triadafilopoulos G. Epidemiology of NSAID-induced GI complications. J Rheumatol 1999; 26:18-24.
6. Vukušić L Štimac D, Čulig J. Cost-efficiency of nonsteroidal anti-inflammatory drug prescribing in Zagreb, Croatia. Coll Antropol 2005; 29:143-7.
7. GorelickBP, Born VRG, D'Agostino BR i sur. Aspirin revisited in light of the introduction of Clopidogrel. Stroke 1999; 30:1716-21.
8. O'Laughlin JC, Hofliezer JW, Ivey KJ. Effect of aspirin on the human stomach in normals: endoscopic comparison of damage produced one hour, 24 hours, and 2 weeks after administration. Scand J Gastroenterol 1981; 16:211-4.
9. Lanza FL. A review of gastric ulcer and gastroduodenal injury in normal volunteers reciving aspirin and other non-steroidal antiinflammatory drugs. Scand J Gastroenterol 1989; 24:24-31.
10. Graham DY, Smith JL, Dobbs SM. Gastric adaptation occurs with aspirin administration in man. Dig Dis Sci 1983; 28:1-6.
11. Laine L, Harper S, Simon Ti sur. A randomized trial comparing the effect of rofecoxib, a COX-2-specific inhibitor, to ibuprofen on the gastroduodenal mucosa of osteoarthritis patients. Gastroenterology 1999; 117: 776-83.
12. Hawkey C, Laine L, Simon Ti sur. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis. A randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2000; 43:370-7.
13. Laine L. Nonsteroidal anti-inflammatory drug gastropathy. Gastrointest Endose Clin North Am 1996; 6:489-504.
14. Adebayo D, Bjarnason I. Is non-steroidal anti-inflammatory drug (NSAID) enteropathy clinically more important than NSAID gastropathy? Postgrad Med J 2006; 82:186-91.
15. Goldstein JL, Eisen GM, Lewis B i sur. Video capsule endoscopy to prospectively assess small bowel injury with colecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol 2005; 3:133-41.
16. Takeuchi K, Smale S, Premchand P i sur. Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2006; 4:157-9.
17. Pairet M, Engelhardt G. Distinct isoforms (COX-1 and COX-2) of Cyclooxigenase: possible physiological and therapeutic implications. Fundam Clin Pharmacol 1996; 10:1-17.
18. ChenevardR, Hurlimann D, Bechir M i sur. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation 2003; 107:405-9.
19. Lichtenberger LM, Wang ZM, Romero JJ. Non-steroidal anti-inflammatory drugs (NSAIDs) associate with zwitterionic phospholipids: insight into the mechanism and reversal of NSAID-induced gastrointestinal injury. Nat Med 1995; 1:154-8.
20. Cryer B, Feldman M. Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal and rectal prostaglandin levels and on mucosal injury. Gastroenterology 1999; 117:17-25.
21. Wallace JL, McKnight W, Reuter B, Vergnolle N. NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology 2000; 119:706-14.
22. Lanza FL, Royer GL, Nelson RS. Endoscopic evaluation of the effects of aspirin, buffered aspirin, and enteric-coated aspirin on gastric and duodenal mucosa. N Engl J Med 1980; 303:136-8.
23. Trondstad RI, Aadland E, Holler T i sur. Gastroscopio findings after treatment with enteric-coated and plain naproxen tablets in healthy subjects. Scand J Gastroenterol 1985; 20:239-42.
24. Silvesteein FE, Faich G, Goldstein JL i sur. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumathoid arthritis: the CLASS study: a randomised controlled trial. JAMA 2000; 284:1247-55.
25. Bombardier C, Laine L, Reicin A i sur. VIGOR study group. Rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343:1520-8.
26. Griffin MR, Piper JM, Daughtery JR i sur. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991; 114:257-63.
27. Piper JM, Ray WA, Daughtery JR i sur. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991; 114:735-40.
28. Simon LS, Hatoum HT, Bittman RM i sur. Risk factors for serious nonsteroidal-induced gastrointestinal complications: regression analysis of the MUCOSA trial. Fam Med 1996; 28:204-10.
29. Weil J, Longman MJS, Wainwright P i sur. Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugs. Gut 2000; 46:27-31.
30. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet treatment, I: prevention of vascular death, MI and stroke by prolonged antiplatelet agents in different categories of patients. Br Med J 1994; 308:235-46.
31. Weisman MS, Graham YD. Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med 2002; 162:2197-202.
32. Feldman M, Shewmake K, Cryer B. Time course inhibition of gastric and platelet COX activity vs acetilsalicylic acid in humans. Am J Physiol Gastrointest Liver Physiol 2000; 279:G 113-G120.
33. Savon JJ, Allen ML, DiMarino AJ Jr i sur. Gastrointestinal blood loss with low dose (325 mg) plain and enteric-coated aspirin administration. Am J Gastroenterol 1995; 90:581-4.
34. Hawkey CJ, Tuillasay Z, Szczepanski L. Helicobacter pylori eradication in patients taking non-steroidal anti-inflammatory drugs: the HELP NSAIDs study. Lancet 1998; 352:1016-21.
35. Feldman M, Cryer B, Mallat D i sur. Role of H. pylori infection on gastroduodenal injury and gastric prostaglandin synthesis during longterm/low-dose aspirin therapy: a prospective-controlled, double-blind randomized trial. Am J Gastroenterol 2001; 96:1751-7.
36. Chan FKL, Chung SCS, Suen BYi sur. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001; 344: 967-73.
37. HorvatD, Vćev A, Soldo I i sur. The results of Helicobacter pylori eradication on repeated bleeding in patients with stomach ulcer. Coll Antropol 2005; 29:139-42.
38. Raskin JB, White RH, Jaszewski R, Misoprostol and ranitidine in the prevention of NSAID-induced ulcers: a prospective, double-blind, multicenter study. Am J Gastroenterol 1996; 91:223-7.
39. ten Wolde S, Dijkmans BA, Hermans J i sur. High-dose ranitidine for the prevention of recurrent peptic ulcer disease in rheumatoid arthritis patients taking NSAIDs. Aliment Pharmacol Ther 1996; 10:347-51.
40. Taha AS, Hundal O, Hawkey CJ. Famotidine for the prevention of gastric and duodenal ulcer caused by nonsteroidal antiinflammatory drugs. N Engl J Med 1996; 34:1435-9.
41. Yeomans ND, Tullasay Z, Juhasz L. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1998; 338:719-26.
42. McDonald TM, Morant SV, Robinson GC. Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study. Br Med J 1997; 315:1333-7.
43. WalanA, Bader J, Classen M i sur. Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. N Engl J Med 1989; 320:69-75.
44. Emery P, Zeidler H, Kvien TK i sur. Colecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised doubleblind comparison. Lancet 1999; 354:2106-11.
45. Bresalier RS, Sandler RS, Quan H i sur. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352:1092-102.
46. Kearney PM, Baigent C, Godwin J i sur. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. Br Med J 2006; 332:1302-8.
47. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA. 2006; 296: 1633-44.
48. Caldwell B, Aldington S, Weatherall M i sur. Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med 2006; 99:132-40.
49. Hernandez-Diaz S, Varas-Lorenzo C, Garcia Rodriguez LA. Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction. Basic Clin Pharmacol Toxicol. 2006; 98:266-74.
50. McAdam BF, Catella-Lawson F, Mardini IA i sur. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 1999; 96:272-7.
51. FDA - Department of Health and Human Services. NSAID package insert labeling template. Dostupno na: http:/www.fda.Gov/cder/drug/infopage/COX2/ NSAIDRxtemplate.pdf. Pristup 24. lipnja 2005.
52. Andersohn F, Suissa S, Garbe E. Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction. Circulation 2006; 113:1950-7.
53. Fitzgerald GA. COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov 2003; 2:879-90.
54. Schmassmann A, Peskar BM, Stettler C i sur. Effects of inhibition of prostaglandin endoperoxide synthasc-2 in chronic gastro-intestinal ulcer models in rats. Br J Pharmacol 1998; 123:795-804.
55. Hawkey CJ, Lungman MJ. Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors. Gut 2003; 52:600-8.
56. Wallace JL, Reuter B, Cicala C i sur. Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat. Gastroenterology 1994; 107:173-9.
57. Davies NM, Roseth AG, Appleyard CB. NO-naproxen vs naproxen: ulcerogenic, analgesis and anti-inflammatory effects. Aliment Pharmacol Ther 1997; 11:69-79.
58. Kurinets A, Lichtenberger LM. Phosphatidylcholine-associated aspirin accelerates healing of gastric ulcers in rats. Dig Dis Sci 1998; 43: 786-90.
59. Lichtenberger LM, Ullou C, Vanous AL. Zwitterionic phospholipids enhance aspirin's therapeutic activity as demonstrates in rodent model systems. J Pharmacol Exp Ther 1996; 277:1221-7.
60. Anand BS, Romero JJ, Sanduja SK i sur. Phospholipid association reduces the gastric mucosal toxicity of aspirin in human subjects. Am J Gastroenterol 1999; 94:1818-22.
61. Henry D, Lim LL, Garcia Rodriguez LA i sur. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative metaanalysis. Br Med J 1996; 312:1563-6.
62. Bocanegra TS, Weaver AL, Tindall EA i sur. Diclofenac/misoprostol compared with diclofenac in the treatment of osteoarthritis of the knee or hip: a randomized, placebo-controlled trail. Arthrotec Osteoarthritis Study Group. J Rheumatol 1998; 25:1602-11.
63. Blot WJ, McLaughlin JK. Over the counter non-steroidal anti-inflammatory drugs and risk of gastrointestinal bleeding. J Epidemiol Biostat 2000; 5:137-42.
64. Garcia Rodriguez LA, Hernandez-Diaz. Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology 2001; 12:570-6.
65. Itoh T. Control of non-malignant chronic pain conditions in Japan and the possible future role of tramadol. Eur J Pain 2001; 5 (Suppl. A):87-9.
66. Scrutinio D, Cimminiello C, Marubini E i sur. Ticlopidine versus aspirin after myocardial infarction (STAMI) trial. J Am Coll Cardiol 2001; 37:1259-65.
67. Machraoui A, Germing A, Lindstaedt M i sur. Efficacy and safety of ticlopidine monotherapy versus ticlopidine and aspirin after coronary artery stenting: follow-up results of a randomizes study. J Invasive Cardiol 2001; 13:431-6.
68. Berger PB, Mahaffey KW, Meier SJ i sur. Safety and efficacy of only 2 weeks of ticlopidine therapy in patients at increased risk of coronary stent thrombosis: results from the Antiplatelet Therapy alone versus Lovenox plus Antiplatelet therapy in patients at increased risk of Stent Thrombosis (ATLAST) trial. Am Heart J 2002; 143:841-6.
69. Medina PJ, Sipols JM, George JN. Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Curr Opinn Hcmatol 2001; 8:286-93.
70. Creager MA. Results of the CAPRIE trail: efficacy and safety of Clopidogrel. Clopidogrel versus aspirin in patients at risk of ischaemic events. Vase Med 1998; 3:257-60.
71. CAPRIE Steering Committee. A randomized, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348:1329-39.
72. Reichenberger F, Wirtz H, Paschke R. Clopidogrel and side effects, Cardiology 2001; 96:51-2.
73. Hallas J, Dall M, Andries A i sur. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. Br Med J 2006; 333:726-31.
74. Hooper L. Brown TJ, Elliott R i sur. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. Br Med J 2004; 329:948-57.
75. Brown TJ, Hooper L, Elliott RA i sur. A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling. Health Technol Assess 2006; 10:1-183.
76. Rostom A, Dube C, Wells G i sur. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev 2002; 4:CD002296.
77. Goldstein JL, Huang B, Amer F, Christopoulos NG. Ulcer recurrence in high-risk patients receiving nonsteroidal anti-inflammatory drugs plus low-dose aspirin: results of a post HOC subanalysis. Clin Ther 2004; 26:1637-43.